Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of ALZ-101

Next Previous
Trial Profile

A Phase 2 study of ALZ-101

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALZ-101 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Alzinova

Most Recent Events

  • 21 Sep 2026 According to an Alzinova media release, the company has launched a rights issue of approximately USD 5.5 million. The net proceeds are intended primarily to fund the initiation of the Phase II clinical study
  • 21 Sep 2026 According to an Alzinova media release, approximately 120 participants with early Alzheimer's disease are planned for enrollment, with the first participant expected around the turn of 2026/2027.
  • 29 Mar 2022 According to an Alzinova media release, company has optimised the manufacturing process of ALZ-101.Process optimisations have resulted in a more efficient and scalable manufacturing process enabling supply of ALZ-101 in the amounts required for phase 2 clinical trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top